<HashMap><database>biostudies-literature</database><scores/><additional><submitter>Crespo-Leiro MG</submitter><funding>CareDx Inc</funding><pagination>2591-601</pagination><full_dataset_link>https://www.ebi.ac.uk/biostudies/studies/S-EPMC5015661</full_dataset_link><repository>biostudies-literature</repository><omics_type>Unknown</omics_type><volume>37(33)</volume><pubmed_abstract>&lt;h4>Aims&lt;/h4>A non-invasive gene-expression profiling (GEP) test for rejection surveillance of heart transplant recipients originated in the USA. A European-based study, Cardiac Allograft Rejection Gene Expression Observational II Study (CARGO II), was conducted to further clinically validate the GEP test performance.&lt;h4>Methods and results&lt;/h4>Blood samples for GEP testing (AlloMap(®), CareDx, Brisbane, CA, USA) were collected during post-transplant surveillance. The reference standard for rejection status was based on histopathology grading of tissue from endomyocardial biopsy. The area under the receiver operating characteristic curve (AUC-ROC), negative (NPVs), and positive predictive values (PPVs) for the GEP scores (range 0-39) were computed. Considering the GEP score of 34 as a cut-</pubmed_abstract><journal>European heart journal</journal><pubmed_title>Clinical usefulness of gene-expression profile to rule out acute rejection after heart transplantation: CARGO II.</pubmed_title><pmcid>PMC5015661</pmcid><funding_grant_id>NCT00761787</funding_grant_id><pubmed_authors>Mohacsi P</pubmed_authors><pubmed_authors>Deng MC</pubmed_authors><pubmed_authors>Parameshwar J</pubmed_authors><pubmed_authors>Schulz U</pubmed_authors><pubmed_authors>Fiocchi R</pubmed_authors><pubmed_authors>Zuckermann A</pubmed_authors><pubmed_authors>Crespo-Leiro MG</pubmed_authors><pubmed_authors>Elashoff B</pubmed_authors><pubmed_authors>Yee JP</pubmed_authors><pubmed_authors>Stypmann J</pubmed_authors><pubmed_authors>Leprince P</pubmed_authors><pubmed_authors>Colvin M</pubmed_authors><pubmed_authors>Hoefer D</pubmed_authors><pubmed_authors>Ross H</pubmed_authors><pubmed_authors>Vanhaecke J</pubmed_authors><pubmed_authors>Zakliczynski M</pubmed_authors><pubmed_authors>Bara C</pubmed_authors></additional><is_claimable>false</is_claimable><name>Clinical usefulness of gene-expression profile to rule out acute rejection after heart transplantation: CARGO II.</name><description>&lt;h4>Aims&lt;/h4>A non-invasive gene-expression profiling (GEP) test for rejection surveillance of heart transplant recipients originated in the USA. A European-based study, Cardiac Allograft Rejection Gene Expression Observational II Study (CARGO II), was conducted to further clinically validate the GEP test performance.&lt;h4>Methods and results&lt;/h4>Blood samples for GEP testing (AlloMap(®), CareDx, Brisbane, CA, USA) were collected during post-transplant surveillance. The reference standard for rejection status was based on histopathology grading of tissue from endomyocardial biopsy. The area under the receiver operating characteristic curve (AUC-ROC), negative (NPVs), and positive predictive values (PPVs) for the GEP scores (range 0-39) were computed. Considering the GEP score of 34 as a cut-</description><dates><release>2016-01-01T00:00:00Z</release><publication>2016 Sep</publication><modification>2026-04-07T19:12:37.066Z</modification><creation>2019-03-26T23:06:41Z</creation></dates><accession>S-EPMC5015661</accession><cross_references><pubmed>26746629</pubmed><doi>10.1093/eurheartj/ehv682</doi></cross_references></HashMap>